ADAP (AIDS Drug Assistance Program)
AIDS Drug Assistance Programs (ADAPs) are state administered programs that provide HIV/AIDS medications to low-income individuals living with HIV disease who have little or no coverage from private or third party insurance. ADAPs were originally authorized by the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, which was enacted in 1990, and reauthorized in 1996 and again in 2000. Currently, ADAPs are authorized under the Ryan White HIV/ADIS Treatment Modernization Act of 2006. The intent of state and federal legislation is to assure that ADAP funds are used only for the purchase of ADAP formulary drugs that cannot be paid for through other sources. ADAP must be the payor of last resort.
ADAP started as a Health Resources and Services Administration (HRSA) demonstration project to provide zidovudine (AZT), the first drug approved by Food and Drug Administration (FDA) to treat HIV infection. Since that time, ADAPs have significantly expanded to cover other FDA approved drugs to treat HIV infection and HIV-related opportunistic infections.
West Virginia AIDS Drug Assistance Program (ADAP) services are available to all eligible residents. To be eligible, HIV infected residents with a family income less than 400% of the federal poverty level who are not eligible for other forms of reimbursement such as Medicaid or full insurance coverage (ADAP will cover co-pays for eligible residents with insurance) must complete the applications at the Department of Health and Human Resources.
The last several years have seen an unprecedented growth in client demand and program costs for ADAP. This is due to:
- The rapid expansion of the HIV/AIDS epidemic among low-income and uninsured populations;
- The high cost of protease inhibitors and other antiretroviral medications that are used in multiple-drug regimens;
- People with HIV/AIDS who are receiving therapy are living longer; and
- The increasing numbers of people with HIV/AIDS seeking combination therapy as a result of widely publicized research that supports new pharmaceutical therapies for improving their health status and quality of life.